Cite
HARVARD Citation
Baize, N. et al. (2020). Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet oncology. 21 (9), pp. 1224-1233. [Online].